Antimutagenicity and Cytotoxicity of the Constituents from the Aerial Parts of Rumex acetosa
作者:Nam-Jae Lee、Jung-Hyun Choi、Byung-Soo Koo、Shi-Yong Ryu、Yeong-Hwan Han、Seung-Il Lee、Dong-Ung Lee
DOI:10.1248/bpb.28.2158
日期:——
Four anthraquinones isolated for the first time from the aerial parts of Rumex acetosa (Polygonaceae), a Korean and a Japanese medicinal plant, and two synthetic derivatives were examined for their cytotoxicities against five cultured human tumor cell lines, i.e. A549 (non-small cell lung), SK-OV-3 (ovary), SK-MEL-2 (melanoma), XF498 (central nerve system) and HCY15 (colon), using the Sulfrhodamine-B method in vitro and antimutagenic activities by Ames test with Salmonella typhimurium TA98 and TA100 and SOS chromotest with E. coli PQ37. Among the tested compounds, emodin strongly inhibited the proliferation of each examined tumor cell line with IC50 values ranged from 2.94 to 3.64 μg/ml and showed potent antimutagenic activities with 71.5% and 53.3% at the concentration of 0.1 mg/plate against the mutagens, NPD and sodium azide, respectively. Its antigenotoxic activity was also very effective at the final concentration of 10 μg/reaction tube against the mutagens, MNNG and NQO by SOS chromotest, reducing the induction factors by 19.6% and 43.5%, respectively. The structure–activity correlation study suggests that an additional OH group at C-6 position in the anthraquinone nucleus may play an important role for their cytotoxicities and an introduction of OH– or OCH3 group at C-6 position is necessary for their antimutagenicities.
METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER
申请人:Haggerty Timothy J.
公开号:US20140335050A1
公开(公告)日:2014-11-13
The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.
Tanaka, Chemical and pharmaceutical bulletin, 1958, vol. 6, p. 203,207